Safety of Hypofractionated Whole-Pelvis Proton Therapy With HDR Boost
Abramson Cancer Center at Penn Medicine
Summary
This is a phase II study of ultrahypofractionated whole pelvis proton therapy with brachytherapy boost for patients with high risk or unfavorable intermediate risk prostate with elevated risk of lymph node involvement.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Pathologic evidence of prostate cancer * Risk group: high or intermediate risk as defined below * High risk: T3a or Gleason Grade Group 4/5 or PSA \>20 * Unfavorable intermediate risk disease: at least one or more of the following: T2b-T2c, Gleason Grade Group 2/3, PSA 10-20, \>50% of cores positive * Must be appropriate for whole pelvis per the treating oncologist or based on lymph node predicting nomogram * Patient is a candidate for definitive external beam radiotherapy: * No prior radiotherapy in the region of study * No inflammatory bowel disease, active c…
Interventions
- RadiationHypofractionated Whole Pelvis Proton Therapy with Brachytherapy Boost
Brachytherapy boost will be delivered and then whole pelvis proton radiation therapy in 5 fractions.
Location
- University of PennsylvaniaPhiladelphia, Pennsylvania